U.S. Patent Application
Patent Application No. 17/987,058, titled “COMPOSITIONS AND METHODS OF TREATMENT OF SICKLE CELL ANEMIA AND BETA-THALASSEMIA” and submitted by Merlin Nithya Gnanapragasam and Mahesh Ramamoorthy, has been published by the United States Patent and Trademark Office. Both are Center for Gene Regulation in Health and Disease (GRHD) researchers.
The invention provides a novel RNA binding protein to treat blood disorders including beta thalassemia and sickle cell anemia. In people with beta thalassemia, low levels of hemoglobin lead to a lack of oxygen in many parts of the body. Affected individuals also have a shortage of red blood cells (anemia) and an increased risk of developing abnormal blood clots.
|
|
FirstIgnite Research Funding Assistance
FirstIgnite can find you the perfect funding partner for your research. Their vetting process combines a proprietary algorithm with a human-in-the-loop approach to ensure best in class company matches and meetings. They provide an AI-powered marketing assistant, empowering academic professionals to market groundbreaking research and innovation at light speed by instantly identifying a wide net of companies interested in your innovations.
The CSU TTO has been offered a 1 month trial period which includes five self-performed targeted marketing campaigns. Patent-pending research is preferred, but non-confidential research projects will also be eligible.
If you would like your research efforts to be considered for this trial run, please contact Jack Kraszewski by June 28th. |